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1 Introduction 
 
Social prescribing is now firmly at the forefront of UK health policy with the recent commitment 
from the Department of Health and Social Care to refer 900,000 people to social prescribing 
schemes by 2024. Alongside this, the NHS Long Term Plan also aims to train 1,000 Social 
Prescribing Link Workers (SPLWs) to work within primary care services by the end of 2020/21 
(DHSC, 2019). Plans are in place to recruit more SPLWs between 2023-24 and have accelerated 
even further during the current pandemic. 
 
The rationale for social prescribing can be presented as follows: (i) the growing pressure on GP 
practices, partly driven by the number of patients who frequently attend a GP with medically 
unexplained symptoms. About, 20% of patients consult their GPs for problems that are primarily 
social rather than medical (Torjesen, 2016); (ii) by 2035, two out of three adults (66%) are expected 
to be living with multiple health conditions and 17% will have four or more conditions. Multi-
morbidities mean that people, often old, need to be supported by a range of health professionals. In 
GP practices, this leads to a shift from ‘treatment’ to ‘management’ of care (Baird et al., 2016) 
which leads to complexity and need for more coordinated care; (iii) growing health inequalities 
which result in long-term medical conditions disproportionately affecting people in deprived areas 
(Marmot, 2020). The recent Marmot review (10 years on) found that life expectancy between the 
most and least deprived areas is 12 years for males and 6 years for females, whilst the differences in 
terms of years of ‘healthy life’ is even starker (15 years for males, 13 years for females); (iv) Early 
mortality for social isolation is as high as established risk factors such as smoking and obesity (Holt 
Lunstad et al, 2015). Thus, tackling social isolation has become an important priority of health 
policy (DCMS, 2018). 
 
In an attempt to seek solutions to these problems, the concept of social prescribing holds significant 
promise. Social prescribing ‘enables healthcare professionals to refer patients to a link worker, to 
co-design a non-clinical social prescription to improve their health and well-being’ (Uni of 
Westminster, 2016; p.19). In addition, social prescribing has the potential to help deliver other 
government priorities in the field of health such as: the merger of health and social care, developing 
and delivering health at the community level and delivering a patient centred approach which 
supports patients to access community activities thereby empowering the patient to decide what is 
right for them.  
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In this context, the Institute for Health and Human Development based (IHHD) at the University of 
East London (UEL) was commissioned by City and Hackney Clinical Commissioning Group 
(CCG) to conduct an evaluation of the social prescribing scheme in Hackney highlighting the key 
changes in different components of quality of life and mental well-being as well as a cost-benefit 
analysis. This report is also a continuation of the first evaluation of social prescribing conducted by 
IHHD (University of East London) and Queen Mary university in 2015 and funded by the Health 
Foundation under the Shine Programme (Bertotti et al., 2015). The survey from this earlier report 
found that general health and wellbeing remained stable over time, whilst qualitative interviews 
with service users revealed overall positive outcomes, with some respondents reporting ‘life 
changing’ experiences. That report did not look at the economic impact of social prescribing which 
is the main focus of this report. In collecting the data for the economic evaluation, we also decided 
to add an assessment of changes in health outcomes, specifically, mental well-being and quality of 
life.  
 
2 Description of the Social Prescribing Service in City and Hackney 
The social prescribing service in City and Hackney is based on a model which involves referrals 
from all 40 GP practices in Hackney and City (East London) to four Social Prescribing Link 
Workers (SPLWs) managed by Family Action, a voluntary sector organisation. During routine 
consultations, General Practitioner may find a patient suitable for social prescribing and refer them 
to a SPLW. Although the majority of referrals come through GP practices, the social prescribing 
scheme does now also receive referrals from other sources. Typically, patients are booked directly 
into appointments where they are assessed by SPLWs, may meet SPLWs up to 6 times, for an 
average session of 30-40 minutes. They provide time, empathy and crucially provide support to 
access non-clinical services offered by the VCSE (Voluntary, Community and Social Enterprise) 
sector in City and Hackney. Family Action currently refers to a total of 150 organisations in both 
voluntary and statutory sectors. The type of support offered by SPLWs is tailored made to each case 
and include not just support with managing health problems but, critically, support with social 
issues such as employment, housing or debt with the view of tackling health inequalities (Marmot et 
al., 2020). Following the publication of the NHS Long Term Plan in early 2019, Primary Care 
Networks (PCN) have been working with CCGs to recruit large number of link workers in order to 
widen the service nationally. However, the City and Hackney social prescribing scheme in this 
report is based specifically on the established CCG component of the service which predates the 
publication of the Long Term Plan.   
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3 Methods 
 
3.1 Study design  
This report assesses the health outcomes - mental well-being and quality of life - and evaluates the 
economic impact of social prescribing using two different approaches to economic analysis. In order 
to conduct this evaluation, we followed a cohort of social prescribing service users as part of the City 
and Hackney social prescribing intervention, over the period between February 2019 and March 2020 
to establish a range of quality of life, mental well-being and social outcomes.  
 
Overall, data from 166 social prescribing service users at baseline, 63 at three months follow up, and 
41 at 6 months follow up were collected by Family Action and the Institute for Health and Human 
Development (IHHD), based at University of East London. It is important to note, however, that 
Family Action assisted a total of 2,000 service users over the period and this may have introduced a 
‘bias’ in the sample selected which may be considered as unrepresentative of the total population of 
service users. Service users with a high level of vulnerability were excluded from the sample. So, for 
instance, people facing eviction or with complex mental health problems were not asked to participate 
as the focus of the session between Social Prescribing Link Worker (SPLW) and user was on 
addressing the immediate need for support rather than completing the questionnaire for the 
evaluation. The exclusion of more vulnerable service users may have led to an underestimation of the 
impact of social prescribing as more vulnerable service users would have been more likely to record 
lower initial scores and ‘potentially’ lead to a greater positive change following social prescribing  
support received.  
 
IHHD provided training to four Family Action SPLWs explaining the aim and objectives of the 
evaluation and discussed data collection and measuring tools. A range of regular management 
meetings between SPLWs and IHHD were also held to monitor the progress of the project. Whilst 
baseline data were collected by the SPLWs face to face, almost all follow up data was collected by 
IHHD via an initial text message linked to an anonymised questionnaire. Ethics approval was 
obtained by University Research Ethics Committee (Ref num: EXP1819 15).  
 
3.2 Cost-effectiveness analysis 
The outcomes quality of life and mental well-being were chosen on the basis of their validity to 
provide a rigorous to economic analysis of quality of life, one based on cost-effectiveness through 
the quality of life measure called EuroQol (EQ-5D-5L), the other based on the well-being valuation 
approach (Trotter, Adams and M-K, 2017). The EQ-5D-5L quality of life tool has been extensively 
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validated (more than 1,000 peer reviewed journal articles). It includes five questions about different 
aspects of life and each question has five possible answers arranged on a Likert scale and representing 
different health states. It enables the calculation of Quality Adjusted Life Years (QALYs) which can 
be combined with cost information and provide a ‘Cost per QALY’. If ‘Cost per QALY’ falls between 
£20,000 and £30,000 per QALY, NICE recommends that the intervention should be considered for 
funding as an NHS intervention (NICE, 2013).  
 
3.3 Social Return on Investment 
 
The other approach to economic analysis is the Social Return on Investment (SROI), a form of 
cost/benefit analysis. In turn, different techniques can be used to calculate SROI. One of these is the 
well-being valuation approach which has not yet been used in evaluations of social prescribing to 
date (Fujiwara, 2013). Yet, the well-being valuation approach has been supported by HM Treasury 
Green Book which includes a range of recommended approaches to economic analysis (HM Treasury, 
2018). The well-being valuation approach is based on a different economic rationale involving the 
use of routine large-scale data (e.g. British Household Panel Survey; Understanding Society, Crime 
Survey for England and Wales). As Trotter et al. (2014) explain, large-scale data is used to identify 
the impact that the target activity (e.g. volunteering) has on self-reported life satisfaction, once 
adjusted for all the other factors that may impact on individuals’ satisfaction levels. Using the same 
statistical techniques, Trotter et al. (2014) calculated the amount of money needed to induce the same 
change in life satisfaction and that constitutes the well-being value for that activity. The advantage of 
this approach is that is uses data from large scale routinely collected studies in order to produce 
financial proxies. It thus therefore represents the opinion of a large number of people.1 
 
In this report, we have been using the valuation approach in conjunction with the work by Trotter, 
Adams and M-K (2017) on mental well-being. They used the well-being valuation approach to 
produce financial proxies for the Short Warwick Edinburgh Mental Well-being Scale (SWEMWBS). 
Thus, for each change in the mental well-being scale, it is possible to derive a financial proxy to be 
used to calculate the return on investment from changes in mental well-being. Using the same well-
 
1 For example, large-scale data is used to identify the impact that volunteering has on self-reported life satisfaction, once adjusted for 
all the other factors that may impact on individuals’ satisfaction levels. This may show that volunteering leads to an average increase 
of 3% in people’s satisfaction levels. Using the same statistical techniques, one can calculate the amount of money needed to induce 
the same change in life satisfaction of 3%, say for example (£5,000). This is the well-being value for that activity.  
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being valuation approach and the associated values from HACT (2018), we also added financial data 
from changes in volunteering, training and drug & alcohol use. 
 
3.4 Data analysis 
The Statistical Package for the Social Sciences (SPSS) was used to analyse data with primary focus 
on the demographic profile, sub-group analysis (i.e. to identify whether specific groups may benefit 
the most from social prescribing), and the economic evaluation which combines an examination of 
QALYs and a social return on investment using the valuation approach for economic analysis. In 
conjunction with SPSS, we have also used a calculator produced by Euroqol which helps with the 
calculation of different states and the creation of QALYs for each user2.  
 
 
 
4 Results 
 
The cohort study followed social prescribing service users over a period of six months (pre-Covid) 
to identify the main changes in quality of life, mental well-being, and other measures needed to 
complete a cost-benefit analysis and cost per QALY (Quality Adjusted Life Years). Overall, data 
from 166 social prescribing service users at baseline, 63 at three months follow up, and 41 at 6 
months follow up. The follow up response rates are significantly lower that baseline. This is due to 
different reasons: (i) social prescribing service users have a lower response rate; (ii) the follow up 
was collected through text messages which have lower response rates than initially expected; (iii) 
SPLWs did not have enough time to collect follow up data. 
 
 
4.1 Descriptive analyses of participant characteristics 
This section provides a descriptive analysis of demographic characteristics of the sample and the 
main changes in quality of life (EQ-5D-5L) and mental well-being (SWEMWBS) over 3 and 6 
months. Table 1 shows the demographic profile of respondents including their age, gender, 
ethnicity, living arrangements, employment status and educational level.  
 
The sample is considerably older and more female than Hackney and City areas overall (Table 1) 
and characterised by a much higher proportion of people of Black/Black British background than 
Hackney and City (31.3% versus 22.4% ).  
 
2 https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/valuation-standard-value-sets/crosswalk-index-value-calculator/ 
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More than one out of three respondents live alone (35.2%). We do not know the total number of 
people living alone in Hackney but from the last Census, we have the proportion of people over 65 
who live alone (42%) in Hackney. In the sample the proportion of people over 65 who live alone 
was 59%, so it is considerably higher than Hackney. A substantial proportion are also ‘unable to 
work due to long term sickness’ (37.9%) and ‘unemployed and looking for work’ (17.4%). These 
two last categories combined show that more than half of the sample (55.3%) are not in work and a 
considerable proportion of respondents (39.4%) have left full time education in their 20s or later, so 
are well educated.  
 
Table 1: Demographic profile of respondents  
Variable Social Prescribing respondents Hackney and City 
Age (*) N % % 
min 20 - max 80 163 48 (Mean) 38 (Mean) 
16-64 136 83.4 92.6 
65+ 27 16.6 7.4 
Gender (**)    
Male  56 33.7 50.0 
Female  110 66.3 50.0 
Ethnicity (***)    
White British 36 22.1 
51.2 White Other 26 16 
Black/Black British 51 31.3 
22.4 Black African 8 4.9 
Asian/Asian British 15 9.2 11.4 
Mixed 6 3.7 
 
14.9 
Chinese 1 0.6 
Any other ethnic background 16 9.8 
Living arrangements    
Alone 56 35.2  
With others (including family) 78 49.1  
Secure housing 17 10.7  
Temporary Accommodation 8 5  
Employment status   (**) 
employed full time 16 9.9 
71.8 employed part time 15 9.3 
self-employed 6 3.7 14.1 
unemployed and looking for work 28 17.4 5.7 
at school or in full time education 4 2.5  
unable to work due to long term sickness 61 37.9  
looking after home/family 6 3.8  
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retired from paid work 19 11.8  
other 6 3.7  
Educational level (age when respondent left 
education)    
I did not receive a formal education 3 1.8  
age 12 or less 6 3.7  
age 13 to 16 47 28.5  
age 17 to 19 32 19.4  
age 20 or over 65 39.4  
I am still in full time education 4 2.4  
Other  
8 4.8  
(*) data from London borough atlas 2015 ; (**) Census estimates only for Hackney; (***) 2018 annual population survey; however, 
ethnic data about City of London are not available   
 
 
4.2 Changes in quality of life  
Quality of life was measured via a validated measuring instrument called EuroQol (EQ-5D-5L). 
This instrument is made up of five components including mobility (ability to walking about), self-
care (ability to wash or dress oneself), usual activities, pain/discomfort, anxiety and/or depression. 
These are arranged along a Likert scale with different health states. Overall, mean quality of life 
over the period declines (Figure 1). This is consistent with the analysis of four out of five 
components of quality of life (mobility, self-care, usual activities, and pain/discomfort) as shown in 
Figure 2. However, it is noticeable that reported ‘anxiety/depression’ declines over the 6 months 
period. It is also important to notice that small changes in few respondents would make for 
significant changes in the overall quality of life score. Changes in the quality of life of just three 
respondents would turn quality of life into a positive score (see sect. 4.5.1). 
 
Figure 1: Overall change in quality of life at 3 and 6 months 
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Figure 2: Quality of life problems reported by respondents 
 
 
 
4.3 Changes in mental well-being   
 
Mental well-being (Table 2) has been measured through the Short Warwick Edinburgh Mental 
Well-being Scale (SWEMWBS) which is a validated scale of seven items used for the measurement 
of mental well-being of any population aged 13 to 74. It comprises of seven positively worded 
statements and participants are asked to rank on a Likert Scale (from ‘None of the time’ to ‘All of 
the time’) each mental well-being statement in the previous two weeks. Mental well-being refers 
here to positive states of being, thinking, behaving and feeling and is a good indicator of how 
people and populations are able to function and thrive (Putz et al 2012)3.  
 
Overall, the mean score shows a positive change which is nearly to be considered ‘meaningful’4 
positive change over the six months period (almost three points change from 18 to 21 (see  Table 2).  
This change is still below the national mean score of 23.6 (nationally representative sample of 7,196 
people) based on the Health Survey for England (2011) which would represent the mean mental 
well-being score for England.  
 
 
 
3 The SWEMWBS includes aspects of mental well-being such as optimism, usefulness, feeling relaxed, 
coping with problems, thinking clearly, closeness to other people, ability to choose 
4 Guideline on mental well-being from (Putz et al., 2012) regards as ‘meaningful’, a change between 3 and 8 
points in SWEMWBS score between baseline and follow up in both positive and negative directions. 
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Table 2: Changes in mental well-being at 3 and 6 months 
 
 
Measure 
 
 
Scale 
Baseline  
(N=162) 
3 months follow up 
(N=64) 
6 months Follow up 
(N=41) 
Mean 
Score  
Min; 
Max  
Mean Score  Min; Max  Mean 
Score  
Min; 
Max  
Mental 
Well-
being 
WEMWB 7-
item metric 
score (on 
scale of 7 to 
35) 
18.4 7; 35 20.7 7; 33 21.0 7;31 
 
It is also noticeable from Table 2 that the rate of increase between baseline and 3 months (2.7 
points) is much higher than between 3 and 6 months (0.3) (Figure 3).  
 
Figure 3: Changes in mental well-being score over time 
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4.4 Participation and health outcomes 
 As part of this evaluation, we monitored ‘actual’ attendance of social prescribing service users to 
community activities. We did this by asking respondents to list the three key activities (if any) they 
had attended as a direct result of social prescribing in the previous three months (Table 3).  
 
At three months follow up (n=63), about half (47.6%) of the sample of respondents had joined at 
least one activity, 17.5% were still waiting. Interestingly, at 6 months the picture is exactly the same 
(n=42). The main activities attended included physical activity (e.g. yoga, general fitness) (42.4%), 
mental well-being/mental health (e.g. Hackney Mind)(15.3%), and Arts/Music (15.3%).  
 
Table 3: Types of community activities attended 
 After 3 months After 6 months 
Community activities attended N % N % 
Social networking (e.g. lunch clubs) 3 5.1 6 16.7 
Volunteering 5 8.5 0 0.0 
Physical activity (e.g. yoga, netball, pilates) 25 42.4 14 38.9 
Gardening groups 2 3.4 1 2.8 
Healthy Eating 3 5.1 1 2.8 
Mental well-being/mental health 9 15.3 7 19.4 
Arts and music 9 15.3 4 11.1 
Other 3 5.1 3 8.3 
Total  59 100.0 36 100.0 
 
 
We also analysed the association between participation to community activities and mental well-
being outcomes. Figure 4 shows low, moderate and high mental well-being (SWEMWBS) for 
respondents who participated to community activities over the period of data collection. If social 
prescribing works and community participation is increased, we would expect the proportion of 
respondents on low MWB to decline and, at the same time, grow in the moderate and high MWB 
groups. This seems to be reflected in Figure 4 below. 
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Figure 4: Participation to community activities and mental well-being 
 
 
 The proportion of respondents with ‘low’ MWB declined from 40% to 10.5% over the 6 months 
period, whilst it increased from 5% to 36.8% in the ‘high’ MWB category. It is interesting to notice, 
however, that moderate MWB increased for the first 3 months (55% to 71.4%) but then declined to 
52.6%. This is consistent with other results of this report which show an increase during the main 
part of the intervention and then a decline in mental well-being. However, this analysis does not 
include any statistical test and is only descriptive. As the sample was not large enough, we could 
not control for other variables such as gender, age, ethnicity in order to provide an accurate picture 
of the association between the two variables (participation and health outcomes) or a causal 
relationship. 
 
In addition to community activities, social prescribing service users also received support with 
social issues such as employment and benefit advice, support with filling in forms (e.g. ESA), and 
help with accessing food vouchers. The vast majority of support in this area was around advice with 
benefits and support from SPLWs on how to access these.  
 
 
4.5 Types of Economic evaluation for social prescribing 
4.5.1 Calculating cost per QALY  
 
Another approach to the economic evaluation of social prescribing is through the quality of life 
measure (EQ-5D-5L) an assessment tool that captures five dimensions of quality of life (mobility, 
self-care, usual activities, pain/discomfort, anxiety/depression).  
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55
5
0
71.4
28.6
10.5
52.6
36.8
0
10
20
30
40
50
60
70
80
Low MWB Moderate MWB High MWB
Participation to community activities (%)
Baseline 3 months Follow up 6 months follow up
14 
 
 
EQ-5D-5L is important for a number of reasons:  
1. It has been extensively validated. More than 1,000 peer reviewed journals 
2. It can be combined with time to calculated QALYs (Quality of Life Adjusted Years). 
QALYs are important because they enable the comparison between the effectiveness of 
different interventions.  
3. If we add the cost of the intervention, we can calculate a cost per QALYs which is used by 
NICE as benchmark for suggestions about investment in a particular intervention. So if the 
cost per QALY is between £20-30K, NICE recommends that the intervention is cost-
effective and should be considered for funding (NICE, 2013).  
 
 
The main objective of this type of economic analysis was to assess whether the cost/QALY for 
social prescribing could fit within the interval set by NHS (£20-30K) which could then be 
considered for funding. In conducting this analysis, we followed Euroqol EQ-5D-5L guidance (Van 
Reenen and Janssen, 2015). We analysed both three and six months data and derived a mean QALY 
by analyzing health states from the quality of life tool (EQ-5D-5L) and multiplying that for the 
average time of the intervention data collection. We then calculated a mean QALY and an 
incremental cost effectiveness ratio (ICER) which provides a cost per QALY. Typically, ICER is 
calculated by dividing the additional cost of the target intervention, compared to usual care by the 
change in QALY between the target intervention and the QALY of usual care. As we do not have 
data about the cost and the QALY of usual care, we used the additional cost per user of providing 
social prescribing and the difference between QALY at baseline and three months.  
 
At both three and 6 months, we found that the ‘QALY gained’ was a negative value5. This means 
that from baseline to the two time points QALY declined as a whole. Under these conditions, there 
is no much point in calculating a cost per QALY as this would not be appropriate with negative 
changes.    
 
However, as the margin between negative and positive QALY gained was extremely tight - 49% of 
respondents recorded a positive value and 51% recorded an overall negative value – we  
 
5 It is important to note that although quality of life as a whole may be negative, its sub-components may 
display some differences. So for instance, in our case, the sub-component anxiety/depression recorded a 
positive change overall. 
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considered a different scenario which is common practice for studies of this kind. We concentrated 
analysis on checking what would have happened if we had turned three respondents from negative 
change to no change in quality of life values (approx. 5% of the sample). This meant that 51% of 
respondents did record a positive change and 49% a negative change. Yet we were interested in 
analyzing what would happen if we had a slightly different scenario which is very close to the 
actual result.  
 
This exercise resulted in a cost per QALY of £20,100, so following NHS guidance of cost-
effectiveness, social prescribing could be considered for funding. However, it is important to note 
here the following limitations:  
(i) this is only one of the different potential scenarios that could be produced by such 
analysis 
(ii) this calculation is based on a small sample of 59 respondents at three months  
(iii) the cost per QALY calculation is based on the three months data (n=59) as it provided 
more data for the calculation than the QALY at six months (n=41) 
(iv) If calculations are taken over a period longer than one year, 3.5% discount needs to be 
applied to the calculation of QALYs.   
(v) the cost per user of delivering social prescribing has been provided by Family Action. It 
does provide an accurate estimate of the true cost. However, the cost per user has been 
derived by the cost of providing the service for 2,000 people. The cost to provide the 
service for 59 service users may be higher or potentially lower than that.  
(vi) The cost calculated here is the cost of delivering the social prescribing service. This does 
not include the cost of activities or services delivered by the voluntary sector or other 
statutory sector agencies.  
 
4.5.2 Social Return on Investment 
 
As mentioned in the methodology section, an alternative approach to economic analysis 
(cost/benefit analysis) is Social Return On Investment (SROI). There are many different approaches 
to calculate SROI (Fujiwara and Campbell, 2011). One of these is the well-being valuation method 
which enables to place a financial value to each point change in the Warwick Edinburgh Mental 
Well-being Scale (Trotter, Adams and M-K, 2017) and also to other changes in service users’ 
situation such as volunteering, training, and use of drug & alcohol. The combination of these value 
offers a social return on investment ratio. The social return on investment ratio is calculated by the 
difference between the financial value of outcomes and the financial value of inputs (cost).  
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Inputs: during the period between 1st Feb 2019 and 30th March 2020, Family Action provided the 
cost for the delivery of social prescribing. These included staff salaries, travel and subsistence, 
volunteer staff time, admin, mobile phone use, postage, rent, and clinical supervision. The total cost 
of delivering the service was calculated at 219, 683.83. During the same period, the number of 
clients assisted was 2,000 which gives a cost per user of £109.84. The number of sessions provided 
to 2,000 service users was 3,947 sessions which makes for an average of 2 sessions per user. 
 
Outcomes: changes in outcomes are calculated between baseline and three months and include 
mental well-being, volunteering, drug& alcohol, and general training which follow the valuation 
approach. We followed guidelines provided by Trotter (2014) which could be interpreted as strict 
but attempt to give a conservative value of SROI rather than potentially falling in the trap of 
providing an overestimation. Following these guidelines, we applied suggested deadweight values 
and restricted the effect of all outcomes to one year, although it is likely that many of these 
outcomes will last much longer than 12 months. 
 
As mentioned above, the mental well-being scale Respondents were asked whether they 
volunteered at three points (baseline, three month and six months follow up). If they did not 
volunteer at baseline but they did volunteer at follow up, the response was recorded as positive, if 
they did volunteer at baseline but did not volunteer at three months follow up, the response was 
recorded as negative alongside the corresponding financial proxy.   
 
The outcomes are calculated over a period of one and two years and include deadweight and drop-
off. Deadweight accounts for attribution. How much of the changes that have recorded would have 
happened without social prescribing? The valuation approach methodology provides deadweight 
values for both changes in health and social circumstances. In our case, mental well-being is 
calculated with a 27% deadweight, whilst volunteering, drug and alcohol and general training are 
calculated at 19%.  
 
Drop-off estimates the loss in the value of the outcomes in future years. We follow guidelines by 
Trotter (2014) which assumed that each outcome last for only one year. This is to account for the 
fact that most outcomes will have a value during or just after the evaluation, but such outcomes are 
likely to lose value over time. We have derived the percentage value of drop-off by analyzing 
changes in each outcome between three and six months outcomes.  
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The final SROI is calculated over a 12 months period and only on the population of respondents 
between baseline and three months follow up (mean 56 people). We used this data because has a 
larger sample than at six months. We adjusted the cost of delivering social prescribing to this 
population of respondents (£23,100). 
 
Table 4 shows a summary of the net positive and negative changes in key outcomes, value of 
financial proxies used as part of the well-being valuation approach and HACT (Trotter 2014; 
HACT, 2018). The final ‘conservative’ Social Return On Investment ratio is £1: £3.51. It means 
that for £1 investment in social prescribing, the annual return for the first year alone is £3.51. This 
is slightly higher than the average of social prescribing schemes which is £1:£2.30 (Polley et al., 
2017). As mentioned, this is a conservative estimate: if we were to include outcomes over a period 
longer than one year, say two years for example, the SROI ratio would increase to £1:£5.77. 
   
Table 4: Outcomes and financial proxies for City and Hackney social prescribing 
Outcome  Data source Net change  Proxy and source Value (£) 
(**) 
Mental well-
being  
Cohort 
study: 
SWEMWBS 
64 (26 net positive 
change) 
Warwick-Edinburgh Mental 
Well-being Scale 
(Trotter et al 2014) 
£61,973.06 
Volunteering Cohort 
Study 
7(net positive change 
is 6) 
Volunteering (£3,249) £3,289.69 
Drug and 
Alcohol 
Cohort 
Study 
3(net positive change 
is 2) 
Drug and Alcohol (£26,124) £15,870.05 
General 
Training 
Cohort 
Study 
2(net benefit change 
is 0) 
General Training (£1331.95) 0 
(**) this value is over 12 months and accounts for deadweight  
 
 
It is important to notice here that the number of people assisted by social prescribing over the period 
of assessment (n=2,000 people) is much larger than the number of respondents at three months 
(n=56). We can provide a SROI estimate extended to the all population of social prescribing service 
users over the period, specifically for mental well-being for which we have stronger data. Following 
baseline data collection, we know that 91% of people at baseline (n=150) reported some 
anxiety/depression. We can estimate that 91% of 2000 people presented with anxiety/depression 
(n=1,820). If these social prescribing service users followed a similar pattern to our actual 
respondents, the SROI would become £1:£8.56. This would only account for changes in mental 
well-being.  
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There are some limitations to the creation of this SROI and the well-being valuation approach: 
- The financial proxies were derived from large scale surveys of the UK population, rather 
than from the sample of social prescribing service users that completed the baseline and 
follow up questionnaires.  
- The last scenario above is only a rough estimate of the potential SROI value for the overall 
population, not a true account measured through data collection from all 2,000 individuals. 
No statistical analysis has been undertaken to assess whether the profile of our sample 
matches the larger sample of service users.  
 
 
5 Discussion  
 
This section discusses the key findings from this evaluation and its policy implications for the 
further development of social prescribing in City and Hackney. Although the data collected pre-date 
the beginning of the pandemic, we discussed the implications of this work for the development of 
the service during the period of the pandemic as the latter has introduced a range of challenges but 
also opportunities for the future implementation of social prescribing.  
 
5.1 Profile of residents is in line with the aims of social prescribing 
 
More than half of the sample (55%) are not in work and a considerable number in long-term 
sickness (37.%), although a significant proportion are well educated (39.4%). Furthermore, a higher 
proportion of respondents over 65 live alone than Hackney (59% in the sample, 42% in Hackney). 
As a result, the target group faces a range of socio-economic issues which are consistent with the 
literature on health inequalities (Marmot et al., 2020) and is one of the key stated aims of social 
prescribing. Mental well-being at baseline (18) was also below the national average (23) which 
indicates that the sample would benefit for a mental well-being type of intervention such as social 
prescribing.  
 
5.2 Quality of life declines but anxiety/depression improves 
 
Overall, quality of life declines over the two period of data collection. However, when  
quality of life is examined in more detail, the component ‘anxiety /depression’ improves over the 
same period. Evidence from other studies using EQ-5D-5L as a quality of life measure appears to 
be broadly consistent with this report. Mercer et al. (2017) found no statistically significant effects 
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of quality of life at 9 months from their cluster RCT. A study on community mentoring for socially 
isolated people (Dickens et al., 2011) did find statistically significant improvement in quality of life, 
but these were lower at follow-up than control. Interestingly, Dayson et al. (2016) and also Moss 
(2015) found small improvements in overall quality of life, but much larger improvements in the 
anxiety/depression component of quality of life. Beyond quality of life, this report found a 
meaningful improvement in mental well-being in line with the anxiety/depression component.  
This evidence reinforces the point that social prescribing improves key aspects of service users’ 
mental health (optimism, usefulness, coping, closeness to other people) considerably more than 
their ability to carry out daily physical tasks (being more mobile, fell less pain/discomfort, being 
able to wash and dress). This may be due to the orientation of the service which provides much 
stronger support with mental health during the sessions between SPLW and service user than other 
components of quality of life.  
 
5.3 Meaningful improvements in mental well-being but not maintained over time 
 
The rate of increase in mental well-being is faster in the first three months and then flattens (Table 
2; Figure 3). This suggests that mental well-being improves when Social Prescribing Link Workers 
(SPLWs) sessions and referral to activity takes place, but then these changes may not be maintained 
over time. Evidence about the improvements in mental health outcomes is consistent with the wider 
literature which found statistically significant improvements in mental well-being using the Short 
version of the Warwick Edinburgh Mental Well-being Scale (Kimberlee, 2016; Brown et al, 2018; 
Bertotti et al., 2018) and noted by the most recent systematic review (Bickerdike et al 2018) and an 
evidence synthesis (Mason et al, 2019). A clear policy outcome here would be strengthening the 
relationship between SPLW and user post referral. Currently, social prescribing SPLWs have a 
policy of contacting all service users, post-referral. This policy is flexible in relation to the time of 
contact that could vary between two to eight weeks, depending on the specific needs of each user.  
 
5.4 Participation and health outcomes 
 
We analysed the data to see whether there is an association between participation to community 
activities as a direct result of social prescribing, and mental well-being outcomes. The expectation is 
that if community participation is sustained over time, mental well-being will improve and there is 
strong evidence that this is the case (e.g. Fancourt, Steptoe and Cadar, 2018). Evidence from this 
report would support this as over the six months period, respondents with high levels of 
participation moved from low to high mental well-being.   
20 
 
 
5.5  ‘Cost per QALY’ calculation 
 
As mentioned above mean quality of life over the period declined. However, we noticed that small 
changes in the quality of life score for just three respondents would change the overall quality of 
life to a positive value. We ‘artificially’ changed the three most negative scores into neutral (5% of 
the total sample). This enabled us to determine a Cost per QALY of £20,100 which would meet 
NICE guidance for a cost-effective intervention. However, it is important to consider that we just 
changed these data artificially, thus this is only an ‘speculative’ exercise and there are some other 
limitations to this finding which are discussed in sect. 4.5.1.   
 
5.6 Above average Social Return on Investment (SROI) 
 
Cost per user is considerably lower (£109 per user) than other social prescribing schemes such as 
Kimberlee (2016) it was £235 per user. The final ‘conservative’ SROI ratio for the sample of 
respondents is £1: £3.51. It means that for £1 investment in social prescribing, the annual return for 
the first year alone is £3.51. We purposefully maintained an extremely conservative approach (for 
more details see sect 4.5.2). Estimates for the overall population of service users (2,000 service 
users) indicate a potential SROI of £1:£8.56.   
 
 
5.7 Changes in service delivery pre-Covid-19  
 
The service in Hackney has changed since its inception. The average number of sessions per user 
has declined to an average of about two sessions per user (2,000 service users for 3,947 sessions 
with SPLWs) and the service provides support for a higher number of users. At the same time, 
reports from stakeholders involved in service delivery reported that the complexity of cases had 
increased pre-Covid-19 and it is clearly an issue during the pandemic. It is difficult to provide 
accurate statistical data on the increased complexity, as it would require an analysis of the overall 
population of users rather than the current sub-sample and such analysis would need to exclude 
social prescribing users who were referred to the service at the end of February 2020. 
 
5.8 Challenges and opportunities for social prescribing during Covid-19:  
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It is clear that the current pandemic has led to a range of radical changes in social prescribing. The 
social prescribing observatory6 which provides a routine data on the development of social 
prescribing referrals shows that since the end of March, the number of social prescribing referrals in 
London have increased substantially with peaks of four times pre-Covid level (Figure 5). 
 
 
Figure 5: Rate of referrals to Social Prescribing 
 
 
Source: Social Prescribing observatory (26th June 2020) 
 
Although data on the development of social prescribing during the pandemic has only started to 
emerge, some of the key challenges include the following:  
1. From face-to-face to online and telephone delivery: It has transformed the delivery of social 
prescribing from face-to-face primarily to a telephone based service. This meant that SPLWs 
need to re-adjust the way they deliver conversation and support users as lack of communication 
through body language has somewhat impaired and weakened the building of trust between 
SPLW and service user. This is an area where further training and research is needed by for 
example learning from the experience of other social prescribing services which have 
traditionally delivered the service over the phone (e.g. Waltham Forest social prescribing).   
2. Adjusting service offer: In some areas, the target service user has changed to readily meet the 
crisis ensued by the pandemic including delivering food and medicine, and providing a brief 
mental health intervention over the phone. This has meant building new contacts within the 
VCSE sector to meet the needs of service users during the pandemic. There has also been a 
decline of community activities on offer as face to face contacts is the basis for most 
 
6 The Social Prescribing Observatory is managed by the University of Oxford, Royal College of General Practice, and also supported 
by NHS England. More details can be found to the following link (please note that the site takes time to load): 
https://clininf.eu/index.php/social-prescribing-observatory-prod/ 
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community activities. In some areas, Redbridge, link workers have adjusted by seeking new 
services, particularly in relation to bereavement and befriending which experienced a much 
higher demand from local service users.   
3. Broadened profile of service users: the profile of service users has broadened to include more 
people facing immediate and urgent issues such as domestic violence and extreme social 
isolation. This led to an increase of SPLWs’ time spent to address these urgent cases and the 
increased need to development risk assessment processes and training to deal specifically with 
these new cases. 
4. Additional pressure on SPLWs: home working and the need to face additional family pressures 
have increased the need to provide support for SPLWs in terms of more frequent clinical 
supervision and the setting up of peer support SPLW groups.  
It is also important to consider some significant opportunities which may provide a route map for 
a more effective delivery of social prescribing in the future: 
1. Engagement of previously dis-engaged GP practices: Many GP practices that have traditionally 
found it difficult to refer patients to social prescribing have started doing so as the pandemic 
crisis pushed them to consider alternatives to their current care. This opened up social 
prescribing to a much source of referrals. 
2. Widened and broadened access: As GP practices needed to provide timely support to 
vulnerable groups, they started asking SPLWs to use GP practices databases to contact 
vulnerable patients. This led to an opening up of the social prescribing service to new people 
whom were not known to the service previously. It is also important to remember that this may 
help to reduce GP consultation rates by offering SPLWs direct access to EMIS databases and 
provide an opportunity for further targeting social prescribing on specific areas of need. 
Alongside this, SPLWs in City and Hackney are now receiving referrals from ‘council helpline’ 
which broadens further the access to social prescribing to a wider group of people who may 
have not visited their GP and may also have different needs.  
3. Changes in service offer: In City and Hackney, the social prescribing service supported a 
greater number of people facing problems with accessing benefit and at risk of housing 
eviction. Emergency grants (up to £200) have been made available to support people with 
immediate needs and other projects to support ‘people with no recurse to public fund’ (e.g. 
people with unclear immigration status) have been set up. Beyond City and Hackney, there are 
also some examples that the lack of face-to-face contact pushed the emergence of online peer 
support groups and other online support activities (e.g. choirs) and the deeper reach into people 
who are housebound and could not access the service prior to Covid-19 as it was not designed 
to be delivered at home.   
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4. Changes in the wider policy landscape: the NHS has set up recruitment of health coaches and 
care coordinators. Provided that a sense of coordination and coherence will accompany these 
changes, the capacity of the system to support people should improve further in the coming 
months. A big question mark remains the ability of the VCSE sector to adapt to a non-face-to-
face delivery of activities. Although support from the government in the form of furlough 
schemes, grants and loans are likely to soften the impact of the pandemic, the medium to long-
term future of the VCSE sector is fragile.  
 
 
6 Key Recommendations 
 
 
6.1 Strengthening longer term support to service users 
 
Consistently with the wider literature, this report confirmed that social prescribing is an intervention 
that leads to ‘meaningful’ improvements in mental well-being (i.e. optimism, usefulness, ability to 
cope, closeness to other people, ability to choose). Greater participation led to important gains in 
mental well-being. However, mental well-being gains appear to be much stronger in the first three 
months and then flatten out over the six months period. City and Hackney social prescribing has an 
established follow up procedure which includes contacting the user flexibly within two to eight 
weeks post-referral.  
 
We suggest that post-referral follow up is strengthened to ensure a longer-term contact 
between Social Prescribing Link Worker and service user. One option may be to increase 
follow up from one to two contacts over two periods (e.g. three months and six months).   
 
This suggestion is likely to be beneficial for the service user but also improve the overall outcomes 
of the service and, crucially, preventing a potential loss of the gains made by SPLWs and service 
users over the initial period.  
 
6.2 Consolidating the current opportunities offered by Covid-19 
 
Whilst the pandemic has created a new set of challenges, the opportunities offered are very 
important for the future of social prescribing. In particular, the shift from a service based on GP 
referrals to a service based on accessing existing databases (e.g. EMIS, council) may provide an 
24 
 
extremely important opportunity to extend social prescribing to a much larger population and 
potentially uncovering additional areas of need that were previously unexplored.  
 
We suggest that in the future a ‘hybrid’ model could be considered where GP referrals are 
used alongside selecting specific target populations (e.g. low/moderate mental health 
problems, living alone, co-morbidities) from GP practice database systems. The inclusion of 
council databases and integration with GP practice data could also be considered as part of 
the wider social prescribing offer across City and Hackney. 
 
6.3 Training for SPLWs 
 
In order to respond to the challenges of Covid-19 and the changing nature of social prescribing - 
with a wider focus on different levels of need (whole population offer) – SPLWs need to 
continuously widen their skill base. Training in how to maximise interaction with service users 
through telephone conversations, the ability to deal with people who face domestic violence, the 
increase use of technology to deliver social prescribing online are some of the examples which 
require addressing in order to sustain an effective workforce. Similarly, good practice from other 
social prescribing interventions may be available. What are the key good practice models that could 
be applied to maximise the support through telephone or video conversations? The experience of 
Waltham Forest social prescribing may be useful here which has traditionally delivered the service 
over the phone.   
 
We suggest that appropriate consideration is given to specialised Social Prescribing Link 
Worker training and intelligence gathering from social prescribing nationally or 
internationally. 
 
6.4 Commissioning further research that captures the impact of COVID-19  
 
As discussed above (sec. 5.8), it is clear that social prescribing has experienced substantial changes 
during Covid-19. Data from this report refer to a pre-Covid period so they cannot tell us anything 
about changes in the profile of service users, their health outcomes, and the challenges as well as 
opportunities of delivering social prescribing in the borough. In addition, this evaluation could only 
analyse a small sample of respondents, whilst the total number of service users was much larger. 
Finally, this evaluation only measured quantitative changes in health outcomes and their economic 
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impact. In order to provide a complete picture of the impact of social prescribing, a series of 
qualitative case studies should be considered as these offer additional insights about the experience 
of service users and their journey of recovery through the social prescribing pathway. 
 
We recommend that an evaluation of the impact of Covid-19 is undertaken by examining 
Family Action database of service users, conducting a range of retrospective case study 
interviews of service users, and focus groups with other stakeholders involved in the delivery 
of social prescribing.  
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